קורונה בישראל: 9,145 מאומתים מחצות | 49,349 פעילים | 327 במצב קשה, מתוכם 165 במצב קריטי | 10,431 נפטרים | 7,797 מאומתים אתמול  

A summary of this information includes the following:
• The suggested dosing regimens for CQ and HCQ as detailed in the Fact Sheets are unlikely to produce an antiviral effect.
• Earlier reports of decreased viral shedding with CQ or HCQ treatment have not been consistently replicated and recent data from a randomized controlled trial assessing robability of negative conversion showed no difference between HCQ and standard of
care alone.
• Current U.S. treatment guidelines do not recommend the use of CQ or HCQ in hospitalized patients with COVID-19 outside of a clinical trial, and the NIH guidelines now recommend against such use outside of a clinical trial.
• Recent data from a large randomized controlled trial showed no evidence of benefit for mortality or other outcomes such as hospital length of stay or need for mechanical ventilation of HCQ treatment in hospitalized patients with COVID-19.

Inherent to all retrospective analyses, our study has certain limitations, such as non-randomisation and blinding of treatment. Also, only the outcome data of the untreated control group based on the public reference were available; because no other data on patient characteristics or clinical symptoms were available, no risk adjustment was possible. Therefore, confounding factors and selection bias, among other issues, might exist. The demographic composition of the treatment group might also have had an influence on our findings.

Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care

This rigorous randomized controlled trial among persons with recent exposure excluded a clinically meaningful effect of hydroxychloroquine as postexposure prophylaxis to prevent SARS-CoV-2 infection.